Singapore well placed for investments in new drugs, says pharma giant MSD

The concept of using mRNA as a medicine had been in the works for as long as 20 years before Covid struck. PHOTO: © BIONTECH SE 2022
New: Gift this subscriber-only story to your friends and family

SINGAPORE - Singapore is set to receive its due share of the deluge of investments flowing into the research and development of new drugs, including mRNA-based vaccines and therapies.

While mRNA vaccines have earned validation through coronavirus jabs, the future of the breakthrough technology they represent goes beyond Covid-19 itself, said Singapore-based David Peacock, who was appointed last month as the Asia-Pacific president of MSD, the international trade name of American pharma giant Merck & Co.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.